SPX3,818.82-12.57 -0.33%
DIA308.28-1.43 -0.46%
IXIC11,296.03-26.21 -0.23%

BRIEF-Fusion Pharmaceuticals Provides Updates On FPI-1434 And FPI-1966 Clinical Programs

reuters.com · 06/09/2022 07:34
BRIEF-Fusion Pharmaceuticals Provides Updates On FPI-1434 And FPI-1966 Clinical Programs

- Fusion Pharmaceuticals Inc FUSN:

  • FUSION PHARMACEUTICALS- IN FPI-1434 TRIAL, EXPECTS TO REPORT PHASE 1 SAFETY, PHARMACOKINETICS, IMAGING DATA, DETAILS ON DOSING REGIMEN, IN H1 2023

  • FUSION PHARMACEUTICALS PROVIDES UPDATES ON FPI-1434 AND FPI-1966 CLINICAL PROGRAMS

  • FUSION PHARMACEUTICALS INC- ALSO UPDATING GUIDANCE FOR FPI-1966 AND EXPECTS TO DOSE FIRST PATIENT IN THIS STUDY IN SECOND HALF OF 2022

Source text for Eikon: [ID:]

Further company coverage: FUSN


((Reuters.Briefs@thomsonreuters.com;))